Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

Acta Neuropathologica

Volumn 126, Issue 6, 2013, Pages 907-915

  Koelsche, Christian ^a,b   Sahm, Felix ^a,b   Capper, David ^a,b   Reuss, David ^a,b   Sturm, Dominik ^a,b   Jones, David T W ^b   Kool, Marcel ^b   Northcott, Paul A ^b   Wiestler, Benedikt ^a,b   Bömer, Katja ^a   Meyer, Jochen ^b   Mawrin, Christian ^c   Hartmann, Christian ^d   Mittelbronn, Michel ^b,e   Platten, Michael ^a,b   Brokinkel, Benjamin ^f   Seiz, Marcel ^g   Herold Mende, Christel ^h   Unterberg, Andreas ^h   Schittenhelm, Jens ⁱ   Weller, Michael ^j   Pfister, Stefan ^a,b   Wick, Wolfgang ^a,b   Korshunov, Andrey ^a,b   Von Deimling, Andreas ^a,b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Astrocytoma; Brain tumor; Glioblastoma; Medulloblastoma; Meningioma; Mutation; Oligodendroglioma; Pediatric; Promoter; TERT

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; ASTROCYTOMA; GENE MUTATION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; NERVOUS SYSTEM TUMOR; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SOLITARY FIBROUS TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84892590846     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1195-5     Document Type: Article

References (33)

1. Abedalthagafi M, Phillips JJ, Kim GE et al (2013) The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Modern Pathology. doi:10.1038/modpathol.2013.90
2. Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267-276
3. Bojesen SE, Pooley KA, Johnatty SE et al (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45:371-384
4. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274
5. Castelo-Branco P, Choufani S, Mack S et al (2013) Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 14:534-542
6. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
7. Durant ST (2012) Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer 3:67-82
8. G ocha AR, Harris J, Groden J (2013) Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression. Mutat Res 743-744:142-150
9. G riewank KG, Murali R, Schilling B et al (2013) TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 109:497-501
10. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469-474
11. Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425
12. Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961
13. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959
14. Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026
15. L anda I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-E1566
16. L iu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar A, Xing M (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603-610
17. L iu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M (2013) Highly prevalent TERT promoter mutations in bladder cancer and gliobastoma. Cell Cycle 12:1637-1638
18. L iu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615-625
19. L ouis D, Ohgaki H, Wiestler O, Cavenee W (2007) World Health Organization classification of tumours of the central nervous system. In: Bosman F, Jaffe E, Lakhani S, Ohgaki H (eds) World Health Organization classification of tumours, 4th edn. IARC, Lyon
20. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Boström J, Wiestler OD, Louis DN, Reifenberger G, von Deimling A (1997) Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151:853-857
21. Nault JC, Mallet M, Pilati C et al (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Commun 4(2218):1-6
22. Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ (2013) Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 23:237-243
23. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. doi:10.1007/s00401-013-1163-0
24. Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H (1997) p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropath Exp Neurol 56:1236-1241
25. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123:853-860
26. Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma and ganglioglioma. Acta Neuropathol 121:397-405
27. Schwartzentruber J, Korshunov A, Liu X et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in pediatric glioblastoma. Nature 482:226-231
28. Schweizer L, Koelsche C, Sahm F et al (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2- STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:651-658
29. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791
30. Vinagre J, Almeida A, Populo H et al (2013) Frequency of TERT promoter mutations in human cancers. Nature Commun 4(2185):1-6
31. Wasylyk B, Hagman J, Gutierrez-Hartmann A (1998) Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23:213-216
32. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister S, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443-451
33. Xu L, Li S, Stohr BA (2013) The role of telomere biology in cancer. Annu Rev Pathol 8:49-78